ChemGenex Launches Trial of Ceflatonin in TKI-Resistant CML

News
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 7
Volume 15
Issue 7

ChemGenex Launches Trial of Ceflatonin in TKI-Resistant CML

MENLO PARK, Calif—Chem-Genex Pharmaceuticals has launched a multinational phase II/III trial of Ceflatonin (homoharringtonine, HHT) in chronic myeloid leukemia patients who have the T315I bcr-abl point mutation, which makes them resistant to tyrosine kinase inhibitors (TKIs) such as imatinib (Gleevec). In April, FDA granted Ceflatonin orphan drug status for the treatment of CML.

Articles in this issue
Surgeons Perform Remote Robotic Animal Nephrectomy Over Public Internet: A First
High-Quality Screening Colonoscopy Priority for GI Docs
Genentech Seeks Expanded Use of Avastin in Breast Cancer
Denosumab Suppresses Bone Resorption in Breast Ca Mets
FDA Approves Priority Review of Merck's Zolinza (Vorinostat)
FDA Approves Revlimid for Myeloma Rx
Real-Time RT Planning, Delivery in the Bronx
Phase III Trial of Enzastaurin for NHL Patients Initiated
Dr. Niederhuber, New Acting Director of NCI, Confronts the Old Problem of an Ever-Declining Institute Budget
Racial Disparities in Prostate Ca Recurrence
HNPCC Pts May Reject Prophylactic Subtotal Colectomy
Improved Colonoscopy Techniques Increase Patient Comfort
New Agents Top Standard Rx in First-Line Advanced RCC
Two Cancer Bills Introduced in the US House of Representatives
Interventions Increase Chemotherapy Center Capacity
Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
A 2-way communication between providers and patients may help facilitate dose modifications to help better manage adverse effects.
Treatment with AML depends on a variety of factors, including stage of treatment, transplant eligibility, and mutational status.
Related Content
Data from the BRUIN-CLL-313 study may support pirtobrutinib as a new potential standard of care for those with untreated CLL or SLL.

Pirtobrutinib Improves PFS in Treatment-Naive CLL/SLL

Sabrina Serani
December 9th 2025
Article

Data from the BRUIN-CLL-313 study may support pirtobrutinib as a new potential standard of care for those with untreated CLL or SLL.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Among patients with NPM1-mutated and KMT2A-rearranged disease, respectively, the ORR was 65% and 41% in the phase 1 KOMET-007 trial.

Ziftomenib Combo Exhibits Tolerability/Early Activity in NPM1/KMT2A+ AML

Roman Fabbricatore
December 8th 2025
Article

Among patients with NPM1-mutated and KMT2A-rearranged disease, respectively, the ORR was 65% and 41% in the phase 1 KOMET-007 trial.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

5-Year+ BRUIN Follow-Up Shows Continued Response With Pirtobrutinib in CLL/SLL

5-Year+ BRUIN Follow-Up Shows Continued Response With Pirtobrutinib in CLL/SLL

Caroline Seymour
December 8th 2025
Article

“Pirtobrutinib continues to show favorable efficacy and promising overall survival [OS],” said William G. Wierda, MD, PhD.

acute lymphoblastic leukemia

Blinatumomab/Ponatinib Provides Chemo-Free Option in Ph+ ALL

Ariana Pelosci
December 7th 2025
Article

Clinical efficacy and response rates were increased with blinatumomab/ponatinib vs chemotherapy/imatinib for patients with Ph+ ALL.